All In Biotech

Drug Trial Radar · NCT01982942

Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Jul 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

255

Actual

Start

Nov 2013

Primary completion

May 2017

Study completion Dec 2017

Sponsor

Lead sponsor
MediciNovaIndustry
Sponsor type
Industry
Collaborators
National Institutes of Health (NIH); National Institute of Neurological Disorders and Stroke (NINDS); National Multiple Sclerosis Society
First posted
Nov 13, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability and activity of ibudilast administered twice daily over a 96 week period in subjects with primary or secondary progressive multiple sclerosis who are currently untreated with long-term MS disease modifying therapy (DMT) or who are receiving either glatiramer acetate (GA) or interferon beta-1, any formulation (IFNβ-1A \[Avonex, Rebif\] or IFNβ-1B \[Betaseron, Extavia\]). Study drug or placebo will be administered to a total of 250 male and female subjects from 21 to 65 years old, inclusive, in two treatment groups. Randomization of subjects will be stratified by disease status (primary progressive multiple sclerosis or secondary progressive multiple sclerosis) and immunomodulating therapy status: current use of immunomodulating therapy or no current use of immunomodulating therapy. The study will consist of a screening phase (up to 30 days) followed by a treatment phase (96 weeks) and a follow-up visit (1 month post Week 96 visit). Following the screening phase, subjects who continue to meet entry criteria will be randomly assigned to 1 of 2 treatment groups: doses up to ibudilast 100 mg/day or matching-placebo in a 1:1 ratio. Study drug will be administered twice daily (BID), e.g., ibudilast 50 mg or placebo taken in the morning and evening).

Conditions

  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Secondary Progressive

Interventions

  • ibudilastDrug

    Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.

  • Placebo oral capsuleDrug

    Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF).Time frame: 96 weeks
  2. Percentage of Participants With Adverse Events.Time frame: 96 weeks

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California Davis

    Davis, California

  • University of California Los Angeles

    Los Angeles, California

  • University of Colorado Denver

    Denver, Colorado

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Emory University

    Atlanta, Georgia

  • Northwestern University

    Evanston, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Washington University School of Medicine in St Louis

    St Louis, Missouri

  • University at Buffalo, The State University of New York

    Buffalo, New York

  • Cornell Medical College

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • University at Stony Brook, The State University of New York

    Stony Brook, New York

  • University at Upstate, The State University of New York

    Syracuse, New York

  • Montefiore Medical Center

    The Bronx, New York

  • University of Cincinnati, Department of Neurology

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Vanderbilt University

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Utah

    Salt Lake City, Utah

  • University of Virginia Charlottesville

    Charlottesville, Virginia

  • Swedish Medical Center - Seattle

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.